Articles related to NEUROLOGICAL DISORDERS

To date, no Cdk5 inhibitor has been approved to treat any neuropsychiatric or degenerative diseases due to challenges at the blood-brain barrier. James Bibb, Ph.D., and colleagues seek to change that notion with their brain-permeable compound, 25-106.

A fact-filled video program all about ALZ-801 (valiltramiprosate), an oral medication with a novel mode of action that aims to slow or stop Alzheimer’s disease altogether.

Hear, watch, or read the top-line observations from a Harris Poll that included more than 360 patients and 120 caregivers on the impact of symptomatic neurogenic orthostatic hypotension (nOH). Suffice, many described severe limitations to their ability to perform activities that are necessary for day-to-day living.

Data for this study came from Danish medical registries over a 20-year period for 247,305 people who visited a hospital or were prescribed antiviral medication for herpes zoster and 1,235,890 people who did not have the disease. These individuals were an average age 64. Up to 21 years later, 9.7% of those with vs. 10.3% of those without herpes zoster developed dementia.

A study published in Nature makes the case that even mild COVID-19 can lead to long-term changes in the human brain. Researchers at Oxford University reported that several months after study participants had COVID-19, they had more gray matter loss and tissue abnormalities, mainly in the areas of the brain associated with smell, and more brain size shrinkage than participants who hadn’t been infected with the virus.

According to the researchers, “The findings from this study suggest that survivors of [HL] require life-long regular screening for early detection of chronic health conditions and that healthy lifestyle behaviors need to be strongly encouraged as these survivors appear more vulnerable to neurocognitive and psychosocial sequelae from these events.”